Israel - English - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 5 mg / 1 ml - fondaparinux - fondaparinux - prevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture major knee surgery or hip replacement surgery. prevention of venous thromboembolic events (vte) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications such as patients undergoing abdominal cancer surgery. prevention of venous thromboembolic events (vte) in adults medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders and/or acute infectious or inflammatory disease. treatment of unstable angina or non-st segment elevation myocardial infarcton (ua/nstemi) in adults for whom urgent ( < 120 mins) invasive management (pci) is not indicated . treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 12.5 mg/ml - fondaparinux - fondaparinux - treatment of adults with acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

Israel - English - Ministry of Health

teva israel ltd - tranexamic acid - tablets - tranexamic acid 500 mg - tranexamic acid - tranexamic acid - treatment of hemorrhage occuring in some forms of surgery, including prostatectomy. hematuria. menorrhagia. hereditary angioneurotic edema.

Israel - English - Ministry of Health

cts ltd - ferrous as iron iii hydroxide sucrose complex - solution for injection - ferrous as iron iii hydroxide sucrose complex 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - venofer is indicated for the treatment of iron deficiency in the following indications:• where there is a clinical need for a rapid iron supply,• in patients who cannot tolerate oral iron therapy or who are non-compliant,• in active inflammatory bowel disease where oral iron preparations are ineffective,• in chronic kidney disease when oral iron preparations are less effective.the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. hb, serum ferritin, tsat, serum iron, etc.)(hb haemoglobin, tsat transferrin saturation)

Israel - English - Ministry of Health

cts ltd - ferrous as iron iii hydroxide sucrose complex - solution for injection - ferrous as iron iii hydroxide sucrose complex 100 mg / 5 ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - venofer is indicated for the treatment of iron deficiency in the following indications:• where there is a clinical need for a rapid iron supply,• in patients who cannot tolerate oral iron therapy or who are non-compliant,• in active inflammatory bowel disease where oral iron preparations are ineffective,• in chronic kidney disease when oral iron preparations are less effective.the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. hb, serum ferritin, tsat, serum iron, etc.)(hb haemoglobin, tsat transferrin saturation)

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - iron sucrose - solution for injection - iron sucrose 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - ferrovin is indicated for the treatment of iron deficiency in the following indications:• where there is a clinical need for a rapid iron supply,• in patients who cannot tolerate oral iron therapy or who are non-compliant,• in active inflammatory bowel disease where oral iron preparations are ineffective,• in chronic kidney disease when oral iron preparations are less effective.the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. hb (haemoglobin),serum ferritin, tsat (transferrin saturation), serum iron, etc.).

Israel - English - Ministry of Health

cts chemical industries ltd, israel - ferrous as iron iii hydroxide polymaltose compl.; folic acid - tablets - folic acid 0.4 mg; ferrous as iron iii hydroxide polymaltose compl. 100 mg - ferrous amino acid complex - ferrous amino acid complex - prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - solution for injection - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - solution for injection - epoetin beta 10000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy. treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - solution for injection - epoetin beta 4000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency and are receiving anti-tumor therapy.